TY - JOUR
T1 - New strategies for active immunotherapy with genetically engineered tumor cells
AU - Pardoll, Drew
PY - 1992
Y1 - 1992
N2 - While previous tumor vaccine strategies have shown intriguing results, clearcut efficacy has been difficult to establish in human trials. Recently, newer approaches have been developed in animal systems that modify tumor cells genetically so that they express new antigens or secrete certain cytokines. Engineering tumor cells to secrete cytokines in a paracrine fashion can induce powerful local cytokine effects without producing significant systemic toxicity. In addition to local inflammation, this approach can alter the presentation of tumor antigen or activation of tumor antigen-specific T lymphocytes, resulting in systemic antitumor immunity.
AB - While previous tumor vaccine strategies have shown intriguing results, clearcut efficacy has been difficult to establish in human trials. Recently, newer approaches have been developed in animal systems that modify tumor cells genetically so that they express new antigens or secrete certain cytokines. Engineering tumor cells to secrete cytokines in a paracrine fashion can induce powerful local cytokine effects without producing significant systemic toxicity. In addition to local inflammation, this approach can alter the presentation of tumor antigen or activation of tumor antigen-specific T lymphocytes, resulting in systemic antitumor immunity.
UR - http://www.scopus.com/inward/record.url?scp=0026730155&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026730155&partnerID=8YFLogxK
U2 - 10.1016/0952-7915(92)90037-F
DO - 10.1016/0952-7915(92)90037-F
M3 - Article
C2 - 1418729
AN - SCOPUS:0026730155
SN - 0952-7915
VL - 4
SP - 619
EP - 623
JO - Current Opinion in Immunology
JF - Current Opinion in Immunology
IS - 5
ER -